keyword
https://read.qxmd.com/read/38626292/bcl2a1-neoepitopes-elicited-cytotoxic-t-lymphocytes-are-a-promising-individualized-immunotherapy-of-pancreatic-cancer
#1
JOURNAL ARTICLE
Shengzhe Lin, Jingwen Hong, Suxin Wu, Chenlu Zhu, Fang Liu, Wansong Lin, Xinran Cai, Yunbin Ye, Yanling Chen
Conventional treatments have shown a limited efficacy for pancreatic cancer, and immunotherapy is an emerging option for treatment of this highly fatal malignancy. Neoantigen is critical to improving the efficacy of tumor-specific immunotherapy. The cancer and peripheral blood specimens from human leukocyte antigen (HLA)-A0201 positive pancreatic cancer patient were subjected to next-generation sequencing and bioinformatics analyses were performed to screen high-affinity and highly stable neoepitopes. The activation of cytotoxic T lymphocytes (CTLs) by the mutBCL2A111-20 neoepitope targeting B-cell lymphoma 2-related protein A1 (BCL2A1) mutant epitope was investigated, and the cytotoxicity of mutBCL2A111-20 neoepitope-specific CTLs to pancreatic cancer cells was evaluated...
April 16, 2024: Journal of Leukocyte Biology
https://read.qxmd.com/read/38625924/immunogenic-profile-of-a-plant-produced-nonavalent-african-horse-sickness-viral-protein-2-vp2-vaccine-in-ifnar-mice
#2
JOURNAL ARTICLE
Martha M O'Kennedy, Robyn Roth, Karen Ebersohn, Lissinda H du Plessis, Sipho Mamputha, Daria A Rutkowska, Ilse du Preez, Jan A Verschoor, Yolandy Lemmer
A safe, highly immunogenic multivalent vaccine to protect against all nine serotypes of African horse sickness virus (AHSV), will revolutionise the AHS vaccine industry in endemic countries and beyond. Plant-produced AHS virus-like particles (VLPs) and soluble viral protein 2 (VP2) vaccine candidates were developed that have the potential to protect against all nine serotypes but can equally well be formulated as mono- and bi-valent formulations for localised outbreaks of specific serotypes. In the first interferon α/β receptor knock-out (IFNAR-/-) mice trial conducted, a nine-serotype (nonavalent) vaccine administered as two pentavalent (5 μg per serotype) vaccines (VLP/VP2 combination or exclusively VP2), were directly compared to the commercially available AHS live attenuated vaccine...
2024: PloS One
https://read.qxmd.com/read/38625508/advances-in-therapeutic-cancer-vaccines-their-obstacles-and-prospects-toward-tumor-immunotherapy
#3
REVIEW
Azadeh Eskandari, Thean Chor Leow, Mohd Basyaruddin Abdul Rahman, Siti Nurbaya Oslan
Over the past few decades, cancer immunotherapy has experienced a significant revolution due to the advancements in immune checkpoint inhibitors (ICIs) and adoptive cell therapies (ACTs), along with their regulatory approvals. In recent times, there has been hope in the effectiveness of cancer vaccines for therapy as they have been able to stimulate de novo T-cell reactions against tumor antigens. These tumor antigens include both tumor-associated antigen (TAA) and tumor-specific antigen (TSA). Nevertheless, the constant quest to fully achieve these abilities persists...
April 16, 2024: Molecular Biotechnology
https://read.qxmd.com/read/38625118/monophosphoryl-lipid-a-based-adjuvant-to-promote-the-immunogenicity-of-multivalent-meningococcal-polysaccharide-conjugate-vaccines
#4
JOURNAL ARTICLE
Kishore R Alugupalli
Activation of the adaptive immune system requires the engagement of costimulatory pathways in addition to B and T cell Ag receptor signaling, and adjuvants play a central role in this process. Many Gram-negative bacterial polysaccharide vaccines, including the tetravalent meningococcal conjugate vaccines (MCV4) and typhoid Vi polysaccharide vaccines, do not incorporate adjuvants. The immunogenicity of typhoid vaccines is due to the presence of associated TLR4 ligands in these vaccines. Because the immunogenicity of MCV4 is poor and requires boosters, I hypothesized that TLR4 ligands are absent in MCV4 and that incorporation of a TLR4 ligand-based adjuvant would improve their immunogenicity...
April 1, 2024: ImmunoHorizons
https://read.qxmd.com/read/38623974/preclinical-pharmacokinetics-and-pharmacology-study-of-rc98-a-programmed-cell-death-ligand-1-monoclonal-antibody-in-cynomolgus-monkeys
#5
JOURNAL ARTICLE
Ling Wang, Qiaoning Li, Chenglian Deng, Zhihao Liu, Fang Wang, Shenjun Li, Lihou Dong, Jing Jiang
INTRODUCTION: RC98 is the monoclonal antibody against Programmed Cell Death Ligand 1 (PD-L1). Relevant reports have confirmed that the influence of PD-L1 expressed by tumor cells on antitumor CD8+ T cell responses is well characterized, but the impact of PD-L1 expressed by immune cells has not been well defined. OBJECTIVE: This study aimed to design a Pharmacokinetics/Pharmacology (PK/PD) study of RC98 in normal cynomolgus monkeys to research the effect on the immune system...
April 15, 2024: Current Pharmaceutical Design
https://read.qxmd.com/read/38623955/the-fusion-of-light-and-immunity-advancements-in-photoimmunotherapy-for-melanoma
#6
REVIEW
Pranav Volety, Carl A Shirley, Gagan Chhabra, Nihal Ahmad
Metastatic melanoma is an aggressive skin cancer with high mortality and recurrence rates. Despite the clinical success of recent immunotherapy approaches, prevailing resistance rates necessitate the continued development of novel therapeutic options. Photoimmunotherapy (PIT) is emerging as a promising immunotherapy strategy that uses photodynamic therapy (PDT) to unleash systemic immune responses against tumor sites while maintaining the superior tumor-specificity and minimally invasive nature of traditional PDT...
April 16, 2024: Photochemistry and Photobiology
https://read.qxmd.com/read/38623820/generation-of-broad-protection-against-influenza-with-di-tyrosine-cross-linked-m2e-nanoclusters
#7
JOURNAL ARTICLE
Logan R Wilks, Gaurav Joshi, Natalie Rychener, Harvinder Singh Gill
Tyrosine cross-linking has recently been used to produce nanoclusters (NCs) from peptides to enhance their immunogenicity. In this study, NCs were generated using the ectodomain of the ion channel Matrix 2 (M2e) protein, a conserved influenza surface antigen. The NCs were administered via intranasal (IN) or intramuscular (IM) routes in a mouse model in a prime-boost regimen in the presence of the adjuvant CpG. After boost, a significant increase in anti-M2e IgG and its subtypes was observed in the serum and lungs of mice vaccinated through the IM and IN routes; however, significant enhancement in anti-M2e IgA in lungs was observed only in the IN group...
April 16, 2024: ACS Infectious Diseases
https://read.qxmd.com/read/38623558/identification-of-lower-grade-glioma-antigens-based-on-ferroptosis-status-for-mrna-vaccine-development
#8
JOURNAL ARTICLE
Zhenxiang Zhao, Na Xing, Hao Guo, Jianfeng Li, Guozhu Sun
PURPOSE: mRNA vaccines represent a promising and innovative strategy within the realm of cancer immunotherapy. However, their efficacy in treating lower-grade glioma (LGG) requires evaluation. Ferroptosis exhibits close associations with the initiation, evolution, and suppression of cancer. In this study, we explored the landscape of the ferroptosis-associated tumor microenvironment to facilitate the development of mRNA vaccines for LGG patients. PATIENTS AND METHODS: Genomic and clinical data of the LGG patients was obtained from the Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) databases...
2024: Pharmacogenomics and Personalized Medicine
https://read.qxmd.com/read/38623200/rationale-for-immune-checkpoint-inhibitors-plus-targeted-therapy-for-advanced-renal-cell-carcinoma
#9
REVIEW
Siwei Yang, Xianrui Yang, Zekai Hou, Liang Zhu, Zhili Yao, Yifei Zhang, Yanzhuo Chen, Jie Teng, Cheng Fang, Songmao Chen, Mingfei Jia, Zhifei Liu, Shaosan Kang, Yegang Chen, Gang Li, Yuanjie Niu, Qiliang Cai
Renal cell carcinoma (RCC) is a frequent urological malignancy characterized by a high rate of metastasis and lethality. The treatment strategy for advanced RCC has moved through multiple iterations over the past three decades. Initially, cytokine treatment was the only systemic treatment option for patients with RCC. With the development of medicine, antiangiogenic agents targeting vascular endothelial growth factor and mammalian target of rapamycin and immunotherapy, immune checkpoint inhibitors (ICIs) have emerged and received several achievements in the therapeutics of advanced RCC...
April 15, 2024: Heliyon
https://read.qxmd.com/read/38622733/correction-targeting-of-focal-adhesion-kinase-enhances-the-immunogenic-cell-death-of-pegylated-liposome-doxorubicin-to-optimize-therapeutic-responses-of-immune-checkpoint-blockade
#10
Baoyuan Zhang, Ning Li, Jiaming Gao, Yuxi Zhao, Jun Jiang, Shuang Xie, Cuiping Zhang, Qingyu Zhang, Leo Liu, Zaiqi Wang, Dongmei Ji, Lingying Wu, Ruibao Ren
No abstract text is available yet for this article.
April 16, 2024: Journal of Experimental & Clinical Cancer Research: CR
https://read.qxmd.com/read/38622691/macrophages-as-carriers-of-boron-carbide-nanoparticles-dedicated-to-boron-neutron-capture-therapy
#11
JOURNAL ARTICLE
Anna Wróblewska, Bożena Szermer-Olearnik, Agnieszka Szczygieł, Katarzyna Węgierek-Ciura, Jagoda Mierzejewska, Dawid Kozień, Paulina Żeliszewska, Roksana Kruszakin, Paweł Migdał, Zbigniew Pędzich, Elżbieta Pajtasz-Piasecka
BACKGROUND: The use of cells as carriers for the delivery of nanoparticles is a promising approach in anticancer therapy, mainly due to their natural properties, such as biocompatibility and non-immunogenicity. Cellular carriers prevent the rapid degradation of nanoparticles, improve their distribution, reduce cytotoxicity and ensure selective delivery to the tumor microenvironment. Therefore, we propose the use of phagocytic cells as boron carbide nanoparticle carriers for boron delivery to the tumor microenvironment in boron neutron capture therapy...
April 15, 2024: Journal of Nanobiotechnology
https://read.qxmd.com/read/38622644/impact-of-doxorubicin-loaded-ferritin-nanocages-ferox-vs-free-doxorubicin-on-t-lymphocytes-a-translational-clinical-study-on-breast-cancer-patients-undergoing-neoadjuvant-chemotherapy
#12
JOURNAL ARTICLE
Marta Sevieri, Francesco Andreata, Francesco Mainini, Lorena Signati, Francesca Piccotti, Marta Truffi, Arianna Bonizzi, Leopoldo Sitia, Claudia Pigliacelli, Carlo Morasso, Barbara Tagliaferri, Fabio Corsi, Serena Mazzucchelli
Despite the advent of numerous targeted therapies in clinical practice, anthracyclines, including doxorubicin (DOX), continue to play a pivotal role in breast cancer (BC) treatment. DOX directly disrupts DNA replication, demonstrating remarkable efficacy against BC cells. However, its non-specificity toward cancer cells leads to significant side effects, limiting its clinical utility. Interestingly, DOX can also enhance the antitumor immune response by promoting immunogenic cell death in BC cells, thereby facilitating the presentation of tumor antigens to the adaptive immune system...
April 15, 2024: Journal of Nanobiotechnology
https://read.qxmd.com/read/38622497/lipids-extracted-from-mycobacterial-membrane-and-enveloped-plga-nanoparticles-for-encapsulating-antibacterial-drugs-elicit-synergistic-antimicrobial-response-against-mycobacteria
#13
JOURNAL ARTICLE
Xueyu Pu, Yuanyuan Wang, Xi Wang, Xiaoqing Sang, Miaomiao Jiang, DaWei Qi, Xin Zhao, Rong Chen, Jianwei Li, Xiang Liu, Zhidong Liu, Jian Yang
Tuberculosis (TB) is a chronic disease caused by Mycobacterium tuberculosis (Mtb), which shows a long treatment cycle often leads to drug resistance, making treatment more difficult. Immunogens present in the pathogen's cell membrane can stimulate endogenous immune responses. Therefore, an effective lipid-based vaccine or drug delivery vehicle formulated from the pathogen's cell membrane can improve treatment outcomes. Herein, we extracted and characterized lipids from Mycobacterium smegmatis , and the extracts contained lipids belonging to numerous lipid classes and compounds typically found associated with mycobacteria...
April 15, 2024: Molecular Pharmaceutics
https://read.qxmd.com/read/38622449/author-correction-breaking-the-performance-ceiling-for-neoantigen-immunogenicity-prediction
#14
Hugh O'Brien, Max Salm, Laura T Morton, Maciej Szukszto, Felix O'Farrell, Charlotte Boulton, Pablo D Becker, Yardena Samuels, Charles Swanton, Marc R Mansour, Sine Reker Hadrup, Sergio A Quezada
No abstract text is available yet for this article.
April 15, 2024: Nature Cancer
https://read.qxmd.com/read/38622425/methods-mechanisms-and-application-prospects-for-enhancing-extracellular-vesicle-uptake
#15
JOURNAL ARTICLE
Ying-Peng Xu, Tao Jiang, Xiao-Fan Yang, Zhen-Bing Chen
Extracellular vesicles (EVs) are considered to be a new generation of bioinspired nanoscale drug delivery systems due to their low immunogenicity, natural functionality, and excellent biocompatibility. However, limitations such as low uptake efficiency, insufficient production, and inhomogeneous performance undermine their potential. To address these issues, numerous researchers have put forward various methods and applications for enhancing EV uptake in recent decades. In this review, we introduce various methods for the cellular uptake of EVs and summarize recent advances on the methods and mechanisms for enhancing EV uptake...
April 16, 2024: Current Medical Science
https://read.qxmd.com/read/38622310/targeting-immunogenic-cell-stress-and-death-for-cancer-therapy
#16
REVIEW
Lorenzo Galluzzi, Emma Guilbaud, Darby Schmidt, Guido Kroemer, Francesco M Marincola
Immunogenic cell death (ICD), which results from insufficient cellular adaptation to specific stressors, occupies a central position in the development of novel anticancer treatments. Several therapeutic strategies to elicit ICD - either as standalone approaches or as means to convert immunologically cold tumours that are insensitive to immunotherapy into hot and immunotherapy-sensitive lesions - are being actively pursued. However, the development of ICD-inducing treatments is hindered by various obstacles...
April 15, 2024: Nature Reviews. Drug Discovery
https://read.qxmd.com/read/38621620/differential-protective-impact-of-peptide-vaccine-formulae-targeting-the-lung-and-liver-stage-of-challenge-schistosoma-mansoni-infection-in-mice
#17
JOURNAL ARTICLE
Hatem Tallima, Menerva M Tadros, Rashika El Ridi
The study aimed to elicit protective immune responses against murine schistosomiasis mansoni at the parasite lung- and liver stage. Two peptides showing amino acid sequence similarity to gut cysteine peptidases, which induce strong memory immune effectors in the liver, were combined with a peptide based on S. mansoni thioredoxin peroxidase (TPX), a prominent lung-stage schistosomula excretory-secretory product, and alum as adjuvant. Only one of the 2 cysteine peptidases-based peptides in a multiple antigenic peptide construct (MAP-3 and MAP-4) appeared to adjuvant protective immune responses induced by the TPX peptide in a MAP form...
April 13, 2024: Acta Tropica
https://read.qxmd.com/read/38619666/peptide-based-vaccine-designing-against-endemic-causing-mammarenavirus-using-reverse-vaccinology-approach
#18
JOURNAL ARTICLE
Dwaipayan Chaudhuri, Joyeeta Datta, Satyabrata Majumder, Kalyan Giri
The rodent-borne Arenavirus in humans has led to the emergence of regional endemic situations and has deeply emerged into pandemic-causing viruses. Arenavirus have a bisegmented ambisense RNA that produces four proteins: glycoprotein, nucleocapsid, RdRp and Z protein. The peptide-based vaccine targets the glycoprotein of the virus encountered by the immune system. Screening of B-Cell and T-Cell epitopes was done based on their immunological properties like antigenicity, allergenicity, toxicity and anti-inflammatory properties were performed...
April 15, 2024: Archives of Microbiology
https://read.qxmd.com/read/38619207/combining-wo3-aunps-with-poly-amidoamine-allows-sensitive-electrochemical-detection-of-dr1-based-on-dual-signal-amplification
#19
JOURNAL ARTICLE
Haiyan Wei, Xiaojing Cui, Huaixia Yang, Fuchun Si, Yaping Zhang
Down-regulator of transcription 1 (DR1) is considered as a biomarker of hashimoto's thyroiditis (HT), which is a risk factor for thyroid cancer. Here, a label-free electrochemical biosensor for DR1 detection was constructed based on polyamidoamine (PAMAM) polymer and the nanocomposite (WO3@AuNPs) composed of tungsten trioxide (WO3) and gold nanoparticles (AuNPs). WO3@AuNPs was obtained by combining monolayer WO3 nanosheets, which has high conductivity, and AuNPs. The modification of WO3@AuNPs can not only increase the conductivity of the electrode but also provide more active sites for signaling units, thus greatly improve the sensitivity of the sensor...
April 15, 2024: ChemPlusChem
https://read.qxmd.com/read/38618960/polyomavirus-positive-merkel-cell-carcinoma-the-beginning-of-the-beginning
#20
JOURNAL ARTICLE
Michael K Wong, Cassian Yee
Merkel cell carcinoma (MCC) is an aggressive, fast-growing, highly metastatic neuroendocrine skin cancer. The Merkel cell polyomavirus (MCPyV) is an oncogenic driver in the majority of MCC tumors. In this issue of the JCI, Hansen and authors report on their tracking of CD8+ T cells reactive to MCPyV T antigen (T-Ag) in the peripheral blood of 26 patients with MCC who were undergoing frontline anti-programmed cell death protein-1 (anti-PD-1) immunotherapy. They discovered unique T cell epitopes and used the power of bar-coded tetramers to portray immune checkpoint inhibitor-induced immunogenicity as a predictor of clinical response...
April 15, 2024: Journal of Clinical Investigation
keyword
keyword
49051
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.